On the other hand, other potential cancer therapies targeting mutant TP53, such as MDM2 inhibitors, zinc metallochaperone-1 (ZMC1) or bispecific antibodies, have shown some efficacies on anticancer treatment [40]. This evidence concerns the gene MDM2 and cancer.